logo-loader
RNS
4basebio PLC

4basebio Plc - Result of AGM & Issue of Options

A blue text on a black backgroundAI-generated content may be incorrect.

4basebio PLC

("4basebio" or the "Company")

 

Result of AGM

Issue of Options

 

 

CAMBRIDGE, UK - 30 June 2026   -   4basebio PLC (AIM: 4BB), a company pioneering an enzymatically-produced DNA technology serving the next generation genetic medicines markets, announces that at the Annual General Meeting held earlier today, all resolutions were duly passed.

 

Issue of Options

Further to the above, on 29 June 2026, the Company granted to employees and a consultant in aggregate 360,000 options over new ordinary shares in the Company. The option exercise prices are based on the mid-market closing price on 1 May 2026 and 29 June 2026 for UK and US employees respectively, subject to their granting criteria. The options to employees vest annually in equal tranches over four years from the vesting start date of 1 May 2026 and the options to the consultant are immediately vested on grant.

 

This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 as amended by regulation 11 of the Market Abuse (Amendment) (EU Exit) Regulations 2019/310.

For further enquiries, please contact:


 4basebio PLC

Dr Amy Walker, CEO

+44 (0)12 2396 7943



 Cairn Financial Advisers LLP (Nominated Adviser)

Jo Turner / Sandy Jamieson / Ed Downes

+44 (0)20 7213 0880



 Cavendish Capital Markets Limited (Joint Broker)

Geoff Nash / Nigel Birks

+44 (0)20 7220 0500



 RBC Capital Markets (Joint Broker)

Kathryn Deegan / Matthew Coakes

+44 (0)20 7653 4000



 ICR Healthcare (Media and Investor Relations)

Mary-Jane Elliott / Jessica Hodgson

+44 (0)203 707 5700



 

 

About 4basebio

4basebio (AIM: 4BB) is a Cambridge-based biotechnology company pioneering the use of synthetic DNA to enable next-generation therapeutics and vaccines. Through its proprietary enzymatic DNA synthesis platform, 4basebio produces GMP-grade synthetic DNA and mRNA with superior speed, purity, and scalability, overcoming the limitations of plasmid-based systems. The company offers application-specific DNA constructs tailored to the diverse needs of gene therapies, genome editing, mRNA production, and DNA vaccines, helping partners accelerate proof-of-concept studies and reach clinical milestones more efficiently while maintaining the highest standards of safety and quality.

 

For more information, visit 4basebio.com .





4369568_0.png




NO INVESTMENT ADVICE

Proactive Investors is a publisher of financial news and information. No content in this record, or published on the Proactive Investors website (the "Site"), constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. No content is tailored to any specific person's needs, objectives, or financial situation.

Proactive Investors is not registered in any category of registration under the securities legislation of any province or territory of Canada. Nothing in this record constitutes "advice" concerning investing in, buying, or selling a security within the meaning of applicable Canadian securities legislation. None of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, or suitability of any particular security, portfolio, transaction, or investment strategy. Any decision to buy, sell, or hold a security should be made only after obtaining advice from a registrant authorised under the securities legislation of your province or territory.

This record, and any record we publish by or on behalf of our clients, should not be construed as an offer or solicitation to buy or sell any product or security. Our content is independent financial journalism, produced in a neutral, objective style with full source attribution. Where Proactive Investors has a commercial relationship with a company covered in this record, that relationship is disclosed within the article. Any such relationship is for news distribution and media services only and does not determine, influence, or shape the editorial content produced.

The Site may contain opinions from time to time regarding securities mentioned in other products, including company-related products, and those opinions may differ from those obtained through another Proactive Investors product. Opinions and commentary reflect the views of the named author at the time of writing and are subject to change without notice.

Price and other data is supplied by sources believed to be reliable. Any calculations are made using such data. Neither the data nor the calculations are guaranteed by those sources, by Proactive Investors, by the information providers, or by any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to previously published articles or opinions. Such references may be selective, may reference only a portion of an article, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

FOR OUR FULL DISCLAIMER CLICK HERE

5 min read